A couple weeks ago we wrote about Deck Bio and its pitch to solve two of the hardest problems in solid tumor immunotherapy at once: going after intracellular antigens and hitting multiple targets simultaneously.
The bet is that a single engineered binder can recognize multiple tumor-specific peptide-MHC complexes and deal with the fact that tumors are heterogeneous and love to evade single-target drugs.
That was the pitch. It represents a completely novel approach – bispecific T cell engager, targeting multiple pMHC.
Well, this week at AACR, they brought data.
Deck presented preclinical results for their lead asset, DBXO-1, a TCR-based bispecific T cell engager built on their dbTCE platform. The molecule is designed to recognize multiple peptide-MHC complexes at the same time, using two in-house technologies called dbTv (TCR variant engineering) and dbSCOPE (specificity optimization).
DBXO-1 preclinical readout
Binding affinity
Nanomolar
T cell activation
Confirmed
Tumor cytotoxicity
Tumor-selective
Off-target
Limited
AACR 2026 presentation. No quantitative IC50s or in vivo tumor regression metrics disclosed.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
The results? Here’s the quick version…
Nanomolar binding affinity across the peptide-MHC complexes.
Robust T cell activation.
Tumor-selective cytotoxicity.
Limited off-target interactions.
Yeah, it’s SUPER early. Yeah, it’s preclinical. But at least they have POSITIVE results, you know? It’s a sign that this is absolutely worth paying attention to moving forward.
Ever since I heard about this company, I’ve had something in the back of my mind though.
The thing nobody knows how to do well in this space is multi-antigen TCR engineering.
Single-antigen pMHC-targeting TCR therapies have been hard enough, and the field is littered with companies that burn cash in discovery or get tripped up by off-target recognition of healthy tissue.
That’s the whole reason Immunocore and Adaptimmune and others have been so cautious about peptide-HLA safety. So, when it comes to Deck Bio, building a binder that hits multiple peptide-MHC targets without accidentally hitting something healthy is a very specific technical problem.
In their data, they mention that they tested binding against ~14,000 normal peptides and found very little off-target activity, similar to a clinically approved pMHC-TCE.
If this specificity optimization actually delivers, the company has something real. If it doesn’t, they’ll find out the hard way in IND-enabling tox.
No clinical stage yet. No IND date. No partnerships announced. What they’ve got is a poster and some encouraging in vitro activity.
That said, competing with platforms like Enara Bio‘s dark antigen TCEs and the broader field of next-generation pMHC-directed therapies is going to take more than a good AACR poster.
We’re watching for IND-enabling tox data and a real first partnership to see if Deck has the platform it says it does.
